Recent studies have shown that a functional interaction between ER and FGFR-mediated pathways may occur toward breast cancer progression, indicating that the simultaneous inhibition of both receptors could be considered in more comprehensive treatments [11,32,33]. This evidence concerns the gene ESR1 and breast carcinoma.